Clinical Trials
271
35 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1965
Active, not recruiting
23
8.5%
Completed
145
53.5%
Enrolling By Invitation
3
1.1%
Not yet recruiting
9
3.3%
Recruiting
57
21.0%
Suspended
1
0.4%
Terminated
7
2.6%
Unknown
26
9.6%
No approval data available
- A fully human antibody targeting oncogenic TGFβ signaling has demonstrated the ability to halt both tumor growth and metastasis in preclinical models of aggressive prostate cancer. - The study, published in Signal Transduction and Targeted Therapy, maps key mechanisms by which cancer cells hijack the TGFβ pathway to drive invasiveness and metastatic spread. - The drug target was shown to be highly expressed in patients with metastatic prostate cancer, with clinical validation contributed by Professor Johann de Bono at the Institute of Cancer Research in London. - MetaCurUm Biotech is advancing the antibody candidate, Meta‑CD, toward clinical development with ongoing safety studies and regulatory preparations.
- The Swedish government has allocated an additional SEK 20 million to Sahlgrenska University Hospital for FOCU.SE, a national precision medicine study focused on drug repurposing for advanced cancer. - A separate SEK 12 million government grant will support SPRINTR, a prostate cancer precision medicine initiative led by Umeå University and Norrland University Hospital, aiming to build a nationwide research platform. - FOCU.SE is a platform study encompassing a trial, exploratory, and data component, testing approved drugs outside their original indications in collaboration with Genomic Medicine Sweden and SciLifeLab. - SPRINTR will enroll patients across at least 23 Swedish clinics, developing scalable IT and workflow solutions to expand precision medicine approaches to additional cancer types over a planned 30-year study period.
- Researchers at KTH Royal Institute of Technology developed a calcium-activated delivery system that improves antibody-drug conjugate penetration into cancer cells by exploiting calcium concentration differences. - The calcium-regulated affinity (CaRA) system binds strongly to EGFR receptors in high-calcium environments outside cells, then releases inside cells where calcium levels are lower. - Testing with mertansine DM1 payload showed extremely low concentrations needed to kill 50% of high EGFR-expressing cancer cells, with no effect on low EGFR-expressing healthy cells. - The technology could enable more precise cancer treatment with lower doses and reduced collateral damage to healthy tissue.
